Are there candidates for high-dose chemotherapy in ovarian carcinoma?-Reference-Cited by-同舟云学术

Are there candidates for high-dose chemotherapy in ovarian carcinoma?

Published:2012-10-16 Issue:1 Volume:31 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Sabatier Renaud,Gonçalves Anthony,Bertucci François,Capiello Maria-Antonietta,Rousseau Frédérique,Lambaudie Eric,Chabannon Christian,Viens Patrice,Extra Jean-Marc

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1756-9966-31-87.pdf

Reference45 articles.

1. National Cancer Institute: http://www.cancer.gov/cancertopics/types/ovarian ,

2. Cannistra SA: Cancer of the ovary. N Engl J Med. 2006, 354: 77-79. 10.1056/NEJMe058308.

3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol. 2005, 17: 93-96. 10.1093/annonc/mdj032.

4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002, 20: 1248-1259. 10.1200/JCO.20.5.1248.

5. International Collaborative Ovarian Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002, 360: 505-515.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Chimiothérapie à hautes doses comme stratégie pour contourner la résistance aux médicaments dans les tumeurs solides;Bulletin du Cancer;2016-10

3. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis;Familial Cancer;2016-02-01

4. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study;Chemotherapy;2015-11-04

5. Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer;Brazilian Journal of Medical and Biological Research;2015-01